138 related articles for article (PubMed ID: 24448834)
1. Genetic variations in TP53 binding sites are predictors of clinical outcomes in prostate cancer patients.
Lin VC; Huang CY; Lee YC; Yu CC; Chang TY; Lu TL; Huang SP; Bao BY
Arch Toxicol; 2014 Apr; 88(4):901-11. PubMed ID: 24448834
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms in oestrogen receptor-binding sites affect clinical outcomes in patients with prostate cancer receiving androgen-deprivation therapy.
Huang CN; Huang SP; Pao JB; Hour TC; Chang TY; Lan YH; Lu TL; Lee HZ; Juang SH; Wu PP; Huang CY; Hsieh CJ; Bao BY
J Intern Med; 2012 May; 271(5):499-509. PubMed ID: 21880074
[TBL] [Abstract][Full Text] [Related]
3. Genetic variants in nuclear factor-kappa B binding sites are associated with clinical outcomes in prostate cancer patients.
Huang SP; Lin VC; Lee YC; Yu CC; Huang CY; Chang TY; Lee HZ; Juang SH; Lu TL; Bao BY
Eur J Cancer; 2013 Nov; 49(17):3729-37. PubMed ID: 23920401
[TBL] [Abstract][Full Text] [Related]
4. Significant associations of prostate cancer susceptibility variants with survival in patients treated with androgen-deprivation therapy.
Bao BY; Pao JB; Huang CN; Pu YS; Chang TY; Lan YH; Lu TL; Lee HZ; Chen LM; Ting WC; Hsieh CJ; Huang SP
Int J Cancer; 2012 Feb; 130(4):876-84. PubMed ID: 21445969
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphisms in androgen receptor-binding sites predict survival in prostate cancer patients receiving androgen-deprivation therapy.
Huang CN; Huang SP; Pao JB; Chang TY; Lan YH; Lu TL; Lee HZ; Juang SH; Wu PP; Pu YS; Hsieh CJ; Bao BY
Ann Oncol; 2012 Mar; 23(3):707-713. PubMed ID: 21652578
[TBL] [Abstract][Full Text] [Related]
6. Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens.
Nguyen PL; Haddad Z; Ross AE; Martin NE; Deheshi S; Lam LLC; Chelliserry J; Tosoian JJ; Lotan TL; Spratt DE; Stoyanova RS; Punnen S; Ong K; Buerki C; Aranes M; Kolisnik T; Margrave J; Yousefi K; Choeurng V; Davicioni E; Trock BJ; Kane CJ; Pollack A; Davis JW; Feng FY; Klein EA
Eur Urol; 2017 Nov; 72(5):845-852. PubMed ID: 28528811
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy.
Huang SP; Huang LC; Ting WC; Chen LM; Chang TY; Lu TL; Lan YH; Liu CC; Yang WH; Lee HZ; Hsieh CJ; Bao BY
Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3068-74. PubMed ID: 19900942
[TBL] [Abstract][Full Text] [Related]
8. Genetic variants in CASP3, BMP5, and IRS2 genes may influence survival in prostate cancer patients receiving androgen-deprivation therapy.
Huang SP; Bao BY; Hour TC; Huang CY; Yu CC; Liu CC; Lee YC; Huang CN; Pao JB; Huang CH
PLoS One; 2012; 7(7):e41219. PubMed ID: 22844442
[TBL] [Abstract][Full Text] [Related]
9. NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy.
Moul JW; Sarno MJ; McDermed JE; Triebell MT; Reynolds MA
Urology; 2014 Dec; 84(6):1427-32. PubMed ID: 25432832
[TBL] [Abstract][Full Text] [Related]
10. Genome-wide detection of allelic genetic variation to predict advanced-stage prostate cancer after radical prostatectomy using an exome SNP chip.
Oh JJ; Park S; Lee SE; Hong SK; Lee S; Jo JK; Lee JK; Ho JN; Yoon S; Byun SS
Urol Oncol; 2015 Sep; 33(9):385.e7-13. PubMed ID: 26087972
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms inside microRNAs and microRNA target sites predict clinical outcomes in prostate cancer patients receiving androgen-deprivation therapy.
Bao BY; Pao JB; Huang CN; Pu YS; Chang TY; Lan YH; Lu TL; Lee HZ; Juang SH; Chen LM; Hsieh CJ; Huang SP
Clin Cancer Res; 2011 Feb; 17(4):928-36. PubMed ID: 21149617
[TBL] [Abstract][Full Text] [Related]
12. Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy.
Zumsteg ZS; Spratt DE; Pei X; Yamada Y; Kalikstein A; Kuk D; Zhang Z; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1012-7. PubMed ID: 22981709
[TBL] [Abstract][Full Text] [Related]
13. Genetic interaction analysis of TCF7L2 for biochemical recurrence after radical prostatectomy in localized prostate cancer.
Chen CS; Huang CY; Huang SP; Lin VC; Yu CC; Chang TY; Bao BY
Int J Med Sci; 2015; 12(3):243-7. PubMed ID: 25678841
[TBL] [Abstract][Full Text] [Related]
14. Genetic variants in the Hippo pathway predict biochemical recurrence after radical prostatectomy for localized prostate cancer.
Huang CY; Huang SP; Lin VC; Yu CC; Chang TY; Juang SH; Bao BY
Sci Rep; 2015 Feb; 5():8556. PubMed ID: 25707771
[TBL] [Abstract][Full Text] [Related]
15. Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy.
Huang SP; Bao BY; Wu MT; Choueiri TK; Goggins WB; Liu CC; Huang CY; Pu YS; Yu CC; Wu TT; Huang CN; Huang CH; Wu WJ
Aging Male; 2012 Mar; 15(1):34-41. PubMed ID: 21615239
[TBL] [Abstract][Full Text] [Related]
16. Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease.
Stenmark MH; Blas K; Halverson S; Sandler HM; Feng FY; Hamstra DA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e335-44. PubMed ID: 21645976
[TBL] [Abstract][Full Text] [Related]
17. The impact of solitary and multiple positive surgical margins on hard clinical end points in 1712 adjuvant treatment-naive pT2-4 N0 radical prostatectomy patients.
Mauermann J; Fradet V; Lacombe L; Dujardin T; Tiguert R; Tetu B; Fradet Y
Eur Urol; 2013 Jul; 64(1):19-25. PubMed ID: 22901983
[TBL] [Abstract][Full Text] [Related]
18. Redefining high-risk prostate cancer based on distant metastases and mortality after high-dose radiotherapy with androgen deprivation therapy.
Tendulkar RD; Reddy CA; Stephans KL; Ciezki JP; Klein EA; Mahadevan A; Kupelian PA
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1397-404. PubMed ID: 21665379
[TBL] [Abstract][Full Text] [Related]
19. Common variants in IGF1 pathway genes and clinical outcomes after radical prostatectomy.
Chang CF; Pao JB; Yu CC; Huang CY; Huang SP; Yang YP; Huang CN; Chang TY; You BJ; Lee HZ; Hour TC; Bao BY
Ann Surg Oncol; 2013 Jul; 20(7):2446-52. PubMed ID: 23397154
[TBL] [Abstract][Full Text] [Related]
20. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
